Brian J Druker
Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles
Fröhling S, Jiang J, Schittenhelm M, Lee B, Griffin J, Stone R, Heinrich M, Deininger M, Druker B, Golub T, Teckie S, Ebert B, Scholl C, Levine R, Loriaux M, Boggon T, Bernard O, Berger R, Döhner H, Döhner K, Gilliland D. Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles. Cancer Cell 2007; 12:501-13.
Dec 1, 2007Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles
Dec 1, 2007Cancer Cell 2007; 12:501-13
Fröhling Stefan, Jiang Jingrui, Schittenhelm Marcus, Lee Benjamin H, Griffin James D, Stone Richard M, Heinrich Michael C, Deininger Michael W, Druker Brian J, Golub Todd R, Teckie Sewit, Ebert Benjamin L, Scholl Claudia, Levine Ross L, Loriaux Marc, Boggon Titus J, Bernard Olivier A, Berger Roland, Döhner Hartmut, Döhner Konstanze, Gilliland D Gary
Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies
Schittenhelm M, Druker B, Deininger M, Bokemeyer C, Lee F, Griffith D, Corbin A, Schroeder A, Shiraga S, Heinrich M. Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. Cancer Res 2006; 66:473-81.
Jan 1, 2006Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies
Jan 1, 2006Cancer Res 2006; 66:473-81
Schittenhelm Marcus, Druker Brian J, Deininger Michael W N, Bokemeyer Carsten, Lee Francis Y, Griffith Diana, Corbin Amie S, Schroeder Arin, Shiraga Sharon, Heinrich Michael C